Dynavax Technologies Corporation (DVAX)

11.21 +0.04 (+0.36%) 收市：04:00PM EDT

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 408

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Ryan Spencer	CEO, Interim CFO & Director	1.49M	無	1978
Mr. David F. Novack	President & COO	1.01M	1.51M	1962
Dr. Robert Janssen M.D.	Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs	861.52k	251.32k	1954
Ms. Kelly MacDonald	Senior VP & CFO (Leave of Absence)	788.55k	無	1984
Mr. Justin Burgess	Chief Accounting Officer & Controller	無	無	無
Mr. Jeff P. Coon	Senior VP & Chief Human Resources Officer	無	無	1963
Mr. Paul Cox	VP of Investor Relations & Corporate Communications	無	無	無
Mr. John L. Slebir	Senior VP & General Counsel	無	無	1966
Mr. Donn Casale	Senior VP & Chief Commercial Officer	無	無	無
Dr. Dong Yu	Senior Vice President of Vaccine Research	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

公司管治

截至 2024年4月1日 止，Dynavax Technologies Corporation 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：5；董事會：5；股東權利：7；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。